ArticleAmerican journal of cancer research2025
Methylation status of PAX1 and SF-1: implications for diagnosis and prognosis in endometrial cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma (EC) is a common malignancy of the female reproductive system, often diagnosed at advanced stages due to the lack of reliable early biomarkers. Gene methylation has emerged as a key epigenetic mechanism in cancer development, offering potential for early detection and prognostic evaluation. This study aimed to explore the methylation status of Paired Box Gene 1 (PAX1) and Steroidogenic Factor 1 (SF-1) as potential biomarkers for EC diagnosis and prognosis. A total of 110 EC patients and 75 non-EC patients, enrolled between January 2020 and January 2022, were retrospective analyzed using methylation-specific polymerase chain reaction (MSP) to assess the clinical utility of PAX1 and SF-1 methylation in diagnosis, prognosis, and recurrence surveillance. EC patients exhibited significantly higher PAX1 and SF-1 methylation levels compared to controls, with SF-1 methylation showing superior diagnostic efficacy (AUC = 0.735). PAX1 methylation was significantly associated with key clinicopathological features, including tumor differentiation grade (P = 0.001), FIGO staging (P < 0.001), and myometrial invasion depth (P = 0.030). It also showed a strong correlation with overall survival (OS) and cumulative incidence of recurrence (CIF) (P < 0.001). These results highlight the important role of PAX1 methylation in the diagnosis and prognostic evaluation of EC. Multivariate Cox regression analysis identified PAX1 methylation positivity as an independent risk factor for poor prognosis, whereas SF-1 methylation had limited prognostic impact. These findings highlight PAX1 methylation as a valuable biomarker for enhancing diagnostic accuracy and refining prognostic stratification in EC. In contrast, SF-1 methylation primarily contributes to diagnosis. Together, these results offer new insights into the development of personalized diagnostic and therapeutic strategies for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.